Conatus Pharmaceuticals Inc. buy tamam
Start price
24.09.15
/
50%
€59.64
Target price
24.03.16
€80.91
Performance (%)
-69.00%
End price
24.03.16
€18.49
Summary
This prediction ended on 24.03.16 with a price of €18.49. The BUY prediction by tamam for Conatus Pharmaceuticals Inc. performed very badly with a performance of -69.00%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Conatus Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0.336% | 4.366% | 21.868% | 63.911% |
| iShares Nasdaq 100 | 0.541% | 3.170% | 7.017% | 108.934% |
| iShares Nikkei 225® | 4.048% | 6.727% | 22.855% | 57.329% |
| iShares S&P 500 | 0.795% | 3.281% | 4.698% | 67.940% |
Comments by tamam for this prediction
In the thread Conatus Pharmaceuticals Inc. diskutieren
tamam stimmt dem eigenen Sentiment von 'Buy' zu
tamam stimmt am 24.09.2015 dem Buy-Crowdsentiment mit dem Kursziel 8.97$ zu.
Top-line results from a 23-subject Phase 2 clinical trial assessing Conatus Pharmaceuticals' (NASDAQ:CNAT) lead product candidate emricasan for the treatment of portal hypertension in patients with liver cirrhosis successfully demonstrated efficacy as determined by two outcome measures.
(Laufzeit überschritten)